What is Kardium?
Kardium Inc. is a specialized medical technology firm dedicated to the advancement of atrial fibrillation treatment through its innovative Globe Pulsed Field System. This integrated platform represents a significant leap in cardiac care, combining high-density mapping with precise pulsed-field ablation in a single, cohesive catheter design. By enabling physicians to visualize complex cardiac activity while simultaneously delivering tailored therapy, Kardium is effectively streamlining the ablation workflow and enhancing procedural precision.
The company's market position is defined by its commitment to patient-specific treatment protocols. By focusing on procedural efficiency and control, Kardium addresses the critical needs of electrophysiologists, positioning itself as a key player in the global cardiovascular device market. Its technology is engineered to reduce the complexity of arrhythmia management, thereby improving clinical outcomes and operational throughput in hospital settings.
How much funding has Kardium raised?
Kardium has raised a total of $497.4M across 6 funding rounds:
Private Equity
$867K
Other Financing Round
$115M
Grant
$5M
Other Financing Round
$104M
Series D
$250M
Unspecified
$22.5M
Private Equity (2010): $867K, investors not publicly disclosed
Other Financing Round (2021): $115M led by Fidelity Management & Research Company and T. Rowe Price Associates
Grant (2022): $5M supported by Government of Canada
Other Financing Round (2024): $104M featuring Fidelity Management Services, Durable Capital Partners, and T. Rowe Price
Series D (2025): $250M backed by Fidelity, Durable Capital Partners, and T. Rowe Price
Unspecified (2026): $22.5M with participation from Government of Canada
Key Investors in Kardium
Fidelity Management & Research Company
A global financial services powerhouse providing comprehensive investment, wealth management, and advisory solutions to a diverse range of institutional and individual clients.
T. Rowe Price Associates
A prominent global asset management organization known for its active investment management, fundamental research, and long-term perspective across diverse asset classes.
Durable Capital Partners
An investment adviser focused on identifying and supporting small-cap compounders within both public and private market ecosystems.
What's next for Kardium?
With the successful completion of its recent funding round, Kardium is well-positioned to accelerate its commercialization efforts and expand the reach of the Globe Pulsed Field System. The strategic focus will likely shift toward scaling manufacturing capabilities, deepening clinical evidence through ongoing trials, and navigating the regulatory pathways required for broader international market penetration. As the company transitions into this next phase of growth, the continued support from institutional investors will be instrumental in maintaining its competitive edge in the rapidly evolving landscape of cardiac rhythm management. The firm remains focused on its core mission of delivering high-precision, efficient solutions that redefine the treatment of cardiac arrhythmias on a global scale.
See full Kardium company page
